Search Results 2091-2100 of 19694 for Hemoglobin

  1. Study of VS-6766 + Adagrasib in KRAS G12C NSCLC Patients - Mayo Clinic

    Adequate hematologic function including: hemoglobin (Hb) ≥ 9.0 g/dL; platelets ≥ 100,000/mm^3; and absolute neutrophil count (ANC) ≥ 1500/mm^3. If a red ...

  2. Type 2 Diabetes Clinical Trials - Mayo Clinic Research

    ... Hemoglobin A1c La Crosse, WI ... Retrospective chart review will also be done to assess objective diabetic control based on most recent hemoglobin A1c.

  3. A Study to Evaluate Tazemetostat Combined with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma - Mayo Clinic

    * Evaluated at least 7 days after last platelet transfusion. c. Hemoglobin ≥9.0 g/dL * May receive transfusion 15. Adequate liver function: 1. Total ...

  4. A Study of Catequentinib, Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma - Mayo Clinic

    Platelet count ≥ 100,000 cells/mm^3, hemoglobin ≥ 9 g/dL, absolute neutrophil count ≥ 1,500 cells/mm^3. Alkaline phosphatase limit ≤ 2.5 x ULN (< 5 x ...

  5. Orthopedic Surgery - Clinical trials

    ... hemoglobin levels, 90-day complications, readmission and reoperation. Pagination Clinical studies. PrevPrevious Page · Go to page 11 · Go to page 22 · Go to ...

  6. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    - Hemoglobin >= 9.0 g/dl - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (Patients with known Gilbert ...

  7. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  8. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  9. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

    * Hemoglobin ≥ 7.0 g/dL ( ≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past ...

  10. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

    Hemoglobin >7.0 g/dL; Absolute neutrophil count (ANC) ≥1000/mcL; growth factor support allowed at physician discretion. Platelet count ≥75,000/mcL; Total ...